Morgan Stanley analyst Thomas Wrigglesworth initiated coverage of Novonesis (NVZMY) with an Overweight rating and DKK 577 price target Novonesis is a “high-quality biotech-based growth compounder” with structural end market drivers to sustain above-peer sales growth and margins, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVZMY: